Non-Invasive Cancer Diagnostics Market Overview

Valued at USD 78.77 billion in 2025, the non-invasive cancer diagnostics market is projected to reach USD 83.92 billion in 2026 and USD 143.60 billion by 2034, growing at a CAGR of 6.9% during the forecast period 2026–2034. Key players include Bio-Rad Laboratories, Inc.; Danaher Corporation; Exact Sciences Corporation; F. Hoffmann-La Roche Ltd.; Foundation Medicine, Inc.; Guardant Health; Illumina; Koninklijke Philips N.V.; QIAGEN N.V.; Siemens Healthineers AG; Sysmex Corporation; and Thermo Fisher Scientific Inc. Historical data in the report covers 2021–2024.

Liquid Biopsy Gains Momentum

By technology, liquid biopsy held a 20.45% share in 2025, and the report identifies liquid biopsy growth as a market driver. Tests that analyze blood, urine, or saliva offer a way to detect cancer without tissue sampling, which supports adoption among clinicians and patients seeking less invasive options. The report does not provide adoption statistics, but the attention given to this technology reflects its growing role.

Molecular Diagnostics Record the Fastest Growth

Molecular diagnostics are the fastest-growing technology segment, with a CAGR of 7.7% during 2026–2034, ahead of the overall market growth rate of 6.9%. For suppliers of assays, sequencing platforms, and analytical instruments, this pace points to rising demand for tests that characterize cancer at the molecular level.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/non-invasive-cancer-diagnostics-market

Biomarker Testing and Imaging Diagnostics

Biomarker testing and imaging diagnostics complete the technology segmentation. The report provides no figures for biomarker testing in its segment analysis. Imaging diagnostics remain an established pillar of non-invasive detection, and manufacturers such as Koninklijke Philips N.V. and Siemens Healthineers AG are among the named key players. Together, these categories show a market that spans laboratory-based and imaging-based approaches.

AI-Enabled Diagnostics as a Trend

AI-enabled diagnostics are identified as a key trend. In October 2025, OraLiva raised USD 2 million in seed funding for an AI platform for non-invasive cancer diagnosis through cytology. In April 2026, PanGIA Biotech revealed a urine-based AI liquid biopsy for prostate cancer, reporting 97.8% sensitivity. These developments show how artificial intelligence is being combined with sample-based testing.

Recent Product Activity

In February 2026, the FDA granted Breakthrough Device designation to ErlySign's saliva-based oral cancer test. In March 2026, Darwin AG launched commercialization of its Multi-Cancer Check blood test, covering 13 cancer types. These events highlight growing investment in non-invasive tests that can screen for several cancers or target specific sites.

Early Detection Demand and Barriers

Demand for early detection is the primary driver. Reimbursement and regulatory barriers are identified as challenges, and the report provides no statistics for either. For technology developers, securing coverage and regulatory clearance is therefore as important as clinical performance in determining commercial success.

Regional Outlook

North America was the largest region in 2025, with a 40.79% share, and the U.S. is the leading country. Europe held a 28% share. Asia Pacific is the fastest-growing region, with a CAGR of 7.5% during the forecast period. The report cites Cancer Atlas data showing that Southern, Eastern, and Southeast Asia account for about 9.2 million new cases and 5.1 million deaths annually.

Market Trajectory

The non-invasive cancer diagnosis is projected to expand from USD 83.92 billion in 2026 to USD 143.60 billion by 2034. Because hospitals held a 44.56% end-user share in 2025 while diagnostic laboratories are the fastest-growing end user, technology suppliers need offerings that fit both institutional and laboratory workflows.

Competitive Landscape and Strategic Outlook

The report names 12 key players: Bio-Rad Laboratories, Danaher Corporation, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Foundation Medicine, Guardant Health, Illumina, Koninklijke Philips N.V., QIAGEN N.V., Siemens Healthineers AG, Sysmex Corporation, and Thermo Fisher Scientific. With a 6.9% CAGR through 2034, companies that combine molecular and sample-based testing with strong evidence and reimbursement support are well positioned to capture growth.

More Trending Latest Reports By Polaris Market Research:

board-games-market

supply-chain-resilience-near-shoring-regionalization-and-market-intelligence-strategies

us-sensitive-compartmented-information-facility-market

top-10-eclinical-solutions-companies-in-2025

surgical-robot-market

top-10-military-drone-manufacturers

simulators-market

bio-based-chemicals-market

computer-aided-design-cad-market